Abstract
The recent introduction of pharmaceutical patent term extension in Chinese Patent Law represents a significant milestone in advancing pharmaceutical innovation. In 2024, more detailed rules for patent term extension became available, as embodied in the amended Implementing Regulations of the Patent Law. Furthermore, clear guidance on the application and examination of patent term extension is provided in the amended Guidelines for Patent Examination, initiating a new phase for the patent term extension system. During the latter half of 2024, decisions were rendered regarding the granting or denial of patent term extensions. These recent developments offer valuable insights for domestic and international stakeholders to effectively utilize and benefit from the system. This article presents a comprehensive overview and analysis of the system, considering legal regulations, eligibility criteria for patent term extension, examination processes and standards, and current progress surrounding this pivotal development.
Get full access to this article
View all access options for this article.